Local 12: Study: Targeted drug therapy slows progression of certain brain tumors
Drug could reduce the need for chemotherapy, radiation and surgery, UC expert says
New research out of the University of Cincinnati shows a targeted drug therapy had positive results in delaying the progression of a specific form of glioma, which is a slow-growing brain tumor.
UC Cancer Center brain tumor specialists said it appears to be an option for treatment and would delay radiation and chemotherapy. Local 12 interviewed Rekha Chaudhary, MD, of the Department of Internal Medicine at the UC College of Medicine who said this drug is given after surgery to remove this kind of tumor and appears to be a powerful player in reducing new growth.
Rekha Chaudhary, MD, of the Department of Internal Medicine at the UC College of Medicine/Photo/Colleen Kelley/UC Marketing + Brand
"This new drug Vorasidenib is an IDH1, IDH2 inhibitor. And what it does, it actually inhibits these receptors that are found, or proteins that are found on the tumors,” Chaudhary said.
Researchers studied 331 people with this disease and compared the study drug to a placebo. Those given the targeted therapy did not have disease progression for more than 27.7 months. For those in the placebo group, it was only 11.1 months.
"Whether this is going to pan out to be a survival benefit in the long run, we don't know. But imagine being 30 years old and not having to go through chemo, radiation, further surgery and just be on this drug for almost three years now, and hopefully longer, is a great benefit to these patients, where we've never had a victory before,” Chaudhary told Local 12.
This targeted treatment was so effective that the patients in the original placebo group whose cancer progressed during the study were switched to the drug. It gives promising new hope.
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's graduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Related Stories
UC co-op helps build career pathways at AtriCure
July 28, 2026
AtriCure, a global medical device company in Mason, Ohio, is UC’s largest biomedical engineering co-op employer, turning University of Cincinnati co-op students into full-time innovators.
Four outstanding preceptors recognized for shaping the next generation of nurses
July 28, 2026
Every nursing student’s journey includes a mentor who helps transform theory into practice. In hospitals, clinics, and community settings, preceptors provide hands-on guidance that helps students build confidence, refine clinical judgment, and develop the skills needed to care for patients independently. Each year, the University of Cincinnati College of Nursing recognizes outstanding clinical educators through its Outstanding Preceptor Awards. Nominated by the students they mentor, the awards honor two prelicensure preceptors and two advanced practice registered nurse (APRN) preceptors — one from the Greater Cincinnati region and one from outside the region —whose commitment to teaching has made an extraordinary impact on student learning and professional development.
CCM Hollywood alumna reminisces on her Cincinnati roots over Skyline
July 28, 2026
Hollywood actress Diana Maria Riva recently sat down with the Cincinnati Enquirer to discuss her career over a Cincinnati staple — Skyline chili. The CCM Acting alumna has worked in Hollywood since the '90s, but she grew up on Cincinnati's West Side.